Participants in this workshop will include a broad range of representatives from the global biopharmaceutical/healthcare industry including manufacturers, regulatory agencies, public and private payers and HTA officials, and academia, among others. Outputs from the workshop will be summarized and made available to all attendees.Objectives 
Elucidate the reimbursement challenges of “Adaptive Pathways” (occasionally referred to as MAPPs or adaptive licensing”) for payers/HTAs and sponsors.
Refine a strategic framework for the ‘right side’ of the “Adaptive Pathways” roadmap:
Creative coverage and reimbursement under clinical utility uncertainty;
Role of real world data for evidence development;
Expanding scope of HTAs: social value, patient preference, combination treatments;
Accounting for variability in clinical practice, patient preference and treatment regimen adherence in HTA analysis and payer schemes;
The challenges of orphan size populations and combination treatments;
Beyond product affordability: impact on system.
Describe elements, factors and findings to include in Janus quantified simulations.
Articulate findings into a call-to-action publication(s) designed to increase awareness and catalyze collaborative and financial support.
Please note that participation is ‘by invitation only.’